1、炎癥性腸病：面臨的問題與挑戰炎癥性腸病：面臨的問題與挑戰Increasing cumulative number of ulcerative colitis and Crohns disease patients in Japan during a 17-year period according to the national registry maintained by the Ministry of Health, Labor and Welfare of the Japanese government Yao T, Matsui T, et al. Dis Colon Rectum 2

2、000;Age- and sex-adjusted annual incidence ofCD and UC in the Songpa-Kangdongdistrict, Seoul, 19862005.Yang SK, et al. Inflamm Bowel Dis 2021New Cases 香港Leong Inflamm Bowel Dis 2004051015202530358586-8990-9293-9596-9899-01YearNew CasesAnnual Incidence of IBD in Hong Kong00.20.40.60.811.21.40.05vEndo

3、scopic healing 26.9 2.9 0.05vSide effect(%) 1.9 10.8 0.05vEffect(%) 47.0 63.3vNo effect(%) 14.0 23.4 vAdverse event(%) 20.0 33.3 0.05vEffect(%) 35.1 32.6vNo effect(%) 15.8 23.3 vAdverse event(%) 8.8 30.2 0.05v* at week 8Treatment of CDvAnalysis of 515 CD patientsv - Aminsalicylates: 57.67%v - Cortic

4、osteroids: 28.74%v - Immunopressants: 4.66%v - Antibiotics: 45.63%v - Chinese medicine: 14.25%v - Surgical treatment: 33.2%J Gastroenterol Hepatol 2006; 21:1009v治療v UC：5-ASA、皮質激素、免疫調理劑v療程、順應癥、療效、副反響v CD： 生物制劑的運用v黏膜愈協作為新的療效規范？v上階梯療法與下階梯療法v 維持治療的方法？長期維持或過度到免疫抑制劑？v 長期治療的擔憂：腫瘤發生率能否升高？IBD 面臨的問題與挑戰中外有關IBD

5、的共識意見v中國炎癥性腸病協作組. 對我國炎癥性腸病診斷治療規范的共識意見(2007)vCarter M J，et al. Guidelines for the management of inflammatory bowel disease in adults. Gut,2004,53(9):V1-16(英國)vTravis S P L, et al. European evidence based consensus on the diagnosis and management of Crohns disease: current managementJ. Gut,2006,55(sup

6、pe 1):i16-i35(歐洲)vLichtenstein G R, et al. American Gastroenterological Association Institute Medical Position Statement on Corticosteroids, Immunomodulators,and Infliximab in Inflammatory Bowel Disease. Gastroenterol, 2006, 130(3):935-939；940-987(美國)最新的共識意見vManagement of Crohn s Disease in Adults Prac